HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christopher Simard Selected Research

tezacaftor

11/2019Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
11/2017Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
11/2017Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christopher Simard Research Topics

Disease

9Cystic Fibrosis (Mucoviscidosis)
01/2020 - 11/2017
2Disease Progression
01/2020 - 01/2018
1Acute Pain
08/2023

Drug/Important Bio-Agent (IBA)

6ivacaftorIBA
01/2020 - 11/2017
5Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA
11/2019 - 11/2017
5ivacaftor drug combination tezacaftorIBA
11/2019 - 11/2017
4ChloridesIBA
11/2019 - 10/2018
3tezacaftorIBA
11/2019 - 11/2017
3elexacaftorIBA
11/2019 - 10/2018
1lumacaftorIBA
11/2018
1CannabinoidsIBA
11/2018
1VX-659IBA
10/2018

Therapy/Procedure

2Therapeutics
11/2017 - 11/2017
1Abdominoplasty
08/2023